HER2 gene amplification – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 gene amplification – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes https://clinicaltrials.eu/trial/study-on-zongertinib-for-treating-advanced-solid-tumors-with-her2-mutations-or-overexpression/ Wed, 29 Apr 2026 14:59:44 +0000 https://clinicaltrials.eu/trial/study-on-zongertinib-for-treating-advanced-solid-tumors-with-her2-mutations-or-overexpression/ This study focuses on patients with HER2-mutated or overexpressed/amplified solid tumors, which are types of cancer where a specific protein called HER2 is either altered or present in higher amounts than normal. The study will test a new medication called zongertinib (also known as BI 1810631) that is given as a film-coated tablet taken by mouth.

The purpose of this research is to evaluate how well zongertinib works in treating various types of advanced cancers that have changes in the HER2 protein. This is an open-label study, which means all participants will receive the active medication. The medication will be given to patients who have already received at least one previous treatment for their advanced cancer.

During the study, participants will take the medication and be monitored for how their cancer responds to the treatment. The study will also look at how long any improvements last and track any side effects that may occur. Participants will also complete questionnaires about their physical functioning and quality of life during the treatment period, which may last up to 15 months.

]]> Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer https://clinicaltrials.eu/trial/study-on-reducing-chemotherapy-in-her2-positive-breast-cancer-using-trastuzumab-pertuzumab-and-paclitaxel-for-patients-with-her2-positive-breast-cancer/ Wed, 29 Apr 2026 14:57:57 +0000 https://clinicaltrials.eu/trial/study-on-reducing-chemotherapy-in-her2-positive-breast-cancer-using-trastuzumab-pertuzumab-and-paclitaxel-for-patients-with-her2-positive-breast-cancer/ This study focuses on patients with HER2-positive breast cancer. The research aims to evaluate whether reducing chemotherapy guided by imaging can be effective when combined with two medications that target HER2: Herceptin (trastuzumab) and Perjeta (pertuzumab). These medications are specifically designed to treat breast cancers that have high levels of a protein called HER2 on their surface.

The treatment plan includes several medications given through intravenous infusion or injection. Patients will receive paclitaxel and carboplatin as chemotherapy drugs, along with Herceptin and Perjeta which target the cancer cells. Some patients may also receive Kadcyla (trastuzumab emtansine), which combines Herceptin with another anti-cancer substance.

Throughout the study, doctors will use imaging tests to monitor how well the treatment is working. Based on these results, they may adjust the amount of chemotherapy given. The main goal is to see if this approach can effectively treat the cancer while potentially reducing the amount of chemotherapy needed. Patients will be monitored for at least three years after starting treatment to evaluate the long-term effectiveness of this approach.

]]>